Nektar Therapeutics Highlights Presentation Of Data From PIVOT-02 Study Of NKTR-214 With Nivolumab In Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference